Posts Archive

NCT04942067: Phase 1/2: APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma...

PRISM High Risk Smoldering Multiple Myeloma NCT04775550: Phase 2: DARA RVD For High Risk SMM (PRISM) The purpose of this research study...

REST NCT04939844: Phase 2: REST - Replacing Steroids in the Transplant Ineligble (REST) Newly diagnosed multiple myeloma patients...

NCT04802356: Phase 2: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients NCT04802356: Phase 2:...

NCT04891809: Phase 2 - Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM As optimal...

NCT04786028: Phase 2 - A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM A...

SABLe NCT04717700: Phase 2: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients...

NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma Newly Diagnosed Multiple Myeloma...

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma Relapsed & Refractory Myeloma NCT04822337:...

NCT04674514: Phase 1/2: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple...

NCT04497961: Phase 2: A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide...

NCT04405167: Phase 1: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma NCT04405167: Phase 1: Tasquinimod for the Treatment...

EQUATE TRIAL EAA181 / EQUATE Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE...

NCT04653246: Phase 2: Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM Isatuximab, Lenalidomide, Bortezomib, and...

The ADVANCE trial Dara-KRd KRd VRd NCT04268498: A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With...

Publication Newly Diagnosed Multiple Myeloma Response-adapted lenalidomide maintenance in newly diagnosed myeloma: phase III GMMG-MM5...

NCT04513639: Phase 2/3: The Relapse From MRD Negativity as Indication for Treatment (REMNANT) Study Dara-Kd The Relapse From MRD...

(ITHACA) High-risk Smoldering Multiple Myeloma NCT04270409 NCT04270409: Phase 3 - Isatuximab in Combination With Lenalidomide and...

NCT04430894: Phase 2: KRDI in Transplant-Eligible MM KRDI in Transplant-Eligible MM This research study is testing the efficacy of an...